Allergan, Novartis deal

The companies will test a combination including a farnesoid X receptor (FXR; NR1H4) agonist from Novartis and cenicriviroc from Allergan in a Phase IIb trial to treat non-alcoholic steatohepatitis (NASH). Two of Novartis’ FXR agonists, both of which have Fast Track designation from FDA, are in Phase II testing for NASH...